Quetiapine, sold under the brand name Seroquel, is one of the most commonly prescribed antipsychotics in the country. It treats schizophrenia, bipolar disorder, and is frequently used off label for insomnia and anxiety. It is also one of a handful of medications documented in the clinical literature to cause a false positive result on a urine drug screen, most often flagging as methadone or as a tricyclic antidepressant (TCA) on an initial immunoassay test. For an employer, clinic, or treatment program, understanding why this happens and how the confirmation process resolves it matters more than reacting to a single non-negative screen.
What Quetiapine Is and Why It Shows Up on a Panel
Quetiapine is a second-generation (atypical) antipsychotic. It is not a controlled substance and it is not chemically related to methadone or to opioids in general. The interference problem is not about quetiapine acting like a drug of abuse in the body. It is about how it interacts with the antibody-based chemistry used in rapid immunoassay screening.
How Immunoassay Screening Actually Works
A standard urine drug test cup or dip card uses an immunoassay: an antibody engineered to bind to a specific drug or drug class, calibrated to react at a set cutoff concentration. These antibodies are built to be sensitive to a family of chemically similar compounds, not to a single exact molecule. That design is what makes rapid screening fast and affordable, and it is also what makes cross-reactivity possible. If a medication or metabolite happens to share enough structural similarity with the target compound, the antibody can bind to it and produce a positive line even though the person never took the drug the panel was built to detect.
A review of urine drug screening for psychiatric pharmacists lays this out directly: immunoassay results are "determined by drug-specific antibody reactivity at a predetermined cutoff concentration," and because of that mechanism, "all immunoassay UDSs possess the potential to produce false positive results," which is why they must be treated as presumptive rather than final. That same review specifically names quetiapine as a documented cause of false positive methadone results on urine drug screens, seen in both case reports and retrospective chart reviews involving adolescent and adult patients, according to a peer-reviewed overview of urine drug screening published on PubMed Central.
The TCA Panel: A Second, Separate Interference
Quetiapine has also been documented to cross-react with tricyclic antidepressant (TCA) immunoassays, which is a different chemical class from methadone entirely. Researchers have traced this to structure: quetiapine has a three-ringed chemical backbone that resembles the ring structure shared by tricyclic antidepressants, and in vitro testing has confirmed that quetiapine and its metabolites can bind to the antibodies used in some commercial TCA immunoassays, according to a case report on quetiapine and false positive TCA testing published on PubMed Central. The authors note it is not fully settled whether the reactivity comes from the parent drug, its active metabolites, or both, but the practical guidance is consistent: a TCA-positive immunoassay in a patient taking quetiapine should not be read at face value.
A separate case report describes a psychiatric patient who tested positive for TCAs on an initial screen after being started on quetiapine, a result that briefly clouded his diagnosis and treatment history before clinicians recognized the interference, as documented in a published case report on quetiapine-associated false positive urine drug screening. That case is a good illustration of why a screen result should never be treated as a diagnosis or a final answer on its own.
Immunoassay Screen vs. Confirmatory Testing
| Factor | Immunoassay (Cup, Dip Card, Point of Care) | GC-MS / LC-MS Confirmation |
|---|---|---|
| What it detects | A drug class, via antibody binding to structurally similar compounds | The exact molecule and its specific metabolites |
| Speed | Minutes, on site | Sent to a laboratory, results take longer |
| Cross-reactivity risk | Present by design, since antibodies target a family of compounds | Not a factor; the method separates and identifies molecules individually |
| Legal and clinical status | Presumptive only, screening level | Confirmatory, evidentiary level |
| Appropriate use for quetiapine cases | Initial screening tool | Required before any positive is treated as final |
Rapid urine drug test dip cards and cups are built for exactly this role: a fast, presumptive first look. They are not designed, and are not intended, to be the last word on a non-negative result. Any program using point of care screening needs a defined pathway to laboratory confirmation for every non-negative, and that pathway is what protects both the person being tested and the organization doing the testing.
Why GC-MS and LC-MS Resolve the Confusion
Gas chromatography-mass spectrometry (GC-MS) and liquid chromatography-tandem mass spectrometry (LC-MS/MS) work on a completely different principle than immunoassay screening. Instead of an antibody reacting to a family of similar compounds, these methods physically separate the components of a sample and identify each one by its precise molecular signature. There is no cross-reactivity at this stage. If a screen flags methadone or a TCA and the person has actually been taking quetiapine, confirmatory testing will not find methadone or a TCA in the sample, because those molecules simply are not there.
This is also a formal requirement in federally regulated testing. Under the Department of Transportation's testing procedures, laboratories may not report a specimen as positive on the basis of an initial immunoassay alone; a positive screen must be confirmed at the molecular level before it is reported as a verified positive, as set out in 49 CFR Part 40, the federal workplace drug testing regulation maintained in the Code of Federal Regulations. Non-regulated employers are not bound by that specific rule, but the same logic applies as sound practice: an unconfirmed screen is not a verified result, and it should never be treated as one.
The MRO Review Process for a Prescribed Antipsychotic
In a regulated or professionally managed testing program, a non-negative laboratory result does not go straight to an employer. It goes to a Medical Review Officer, a licensed physician trained to review laboratory findings and determine whether a legitimate medical explanation exists before a result is ever verified as positive. Under the SAMHSA guidance that trains MROs for this role, the officer contacts the person tested, asks about current medications and relevant medical history, and reviews documentation such as a valid prescription when one applies, all before the result is reported to the employer as positive, negative, or otherwise, according to the SAMHSA Medical Review Officer Guidance Manual.
For a person taking quetiapine as prescribed, this is the step where the discrepancy gets sorted out. The MRO can request laboratory confirmation, review the prescription, and correlate the pharmacology with the flagged panel. A verified prescription for quetiapine, combined with a confirmatory test that does not detect methadone or a TCA at the molecular level, resolves the case. What it does not do, and should never do, is result in advice to change, stop, or adjust the medication itself. That decision belongs to the prescribing clinician and the patient, not to a drug testing program.
What Employers and Programs Should Do
- Treat every immunoassay result as presumptive, never as a final determination on its own.
- Route every non-negative result through laboratory confirmation before any employment, clinical, or program action is taken.
- Let a Medical Review Officer or equivalent qualified reviewer handle prescription verification rather than asking a supervisor or collector to make that call.
- Keep the reason for a request to explain a positive screen private and limited to what is necessary for the review.
- Never instruct or suggest that someone alter a prescribed medication schedule around a test date. That is a decision for a treating clinician, and testing staff should not weigh in on it.
Programs that regularly encounter TCA or methadone flags may find it useful to understand exactly what each of those panels is designed to catch and why they are structured the way they are, covered in our articles on how TCA drug test panels work and on what the methadone (MTD) panel actually detects.
Frequently asked questions
Does Seroquel actually contain anything similar to methadone or antidepressants?
No. Quetiapine is not chemically related to methadone. The interference with TCA immunoassays has been linked to a structural similarity in quetiapine's ring structure, which can cause the antibody used in some TCA screening tests to bind to it. The methadone interference is documented in case reports and chart reviews, but it reflects assay cross-reactivity, not a shared chemical identity between the two drugs.
If someone on quetiapine screens positive, does that mean the lab made an error?
Not necessarily an error. The immunoassay did what it was designed to do, which is flag a chemical signal above a cutoff. It is a screening tool built for speed and broad sensitivity, not molecular precision. That is exactly why confirmatory testing exists, to determine at the molecular level whether the flagged substance is actually present.
Should someone stop taking Seroquel before a drug test to avoid a false positive?
No. Stopping or altering a prescribed antipsychotic without medical guidance carries its own health risks and is not something a testing program should ever suggest. The correct path is disclosure to the Medical Review Officer or collection staff and reliance on laboratory confirmation, not changing the medication.
Can a rapid dip card or cup by itself confirm quetiapine caused the result?
No. A dip card or cup performs the same class of antibody-based immunoassay screening described here, and it carries the same presumptive limitations. Only laboratory-based GC-MS or LC-MS testing can identify the specific molecules in a sample and distinguish an actual methadone or TCA finding from a false positive caused by quetiapine.
Does this mean quetiapine will always cause a false positive?
No. Cross-reactivity depends on the specific immunoassay platform, its antibody design, and its cutoff concentration, and results vary across manufacturers and panel types. Not every quetiapine user will trigger a false positive, and not every methadone or TCA flag in a quetiapine patient is automatically false. That determination is exactly what confirmatory testing and MRO review are for.
This article is general information, not medical or legal advice. It is not a substitute for guidance from a prescribing clinician, a Medical Review Officer, or qualified legal counsel, and it should not be used to interpret an individual drug test result.
